| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918163 | Radiotherapy and Oncology | 2015 | 7 Pages |
Abstract
The combination of short-course radiotherapy and rapamycin turned out to be feasible, provided that the interval between neo-adjuvant treatment and surgical resection is at least 6Â weeks. Although from this cohort no clear increase in pCR could be observed, a clear metabolic response after rapamycin run-in was observed, indicating a biological activity of this drug in rectal cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jeroen Buijsen, Jørgen van den Bogaard, Barry Jutten, Eric Belgers, Meindert Sosef, Jeroen W.A. Leijtens, Geerard L. Beets, Rob L.H. Jansen, Robert G. Riedl, Ruud Clarijs, Guido Lammering, Philippe Lambin,